Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel Insulin Lispro Formulation in Patients With Type 2 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 27 Jun 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to Change in clinical strategy.
- 21 Nov 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 21 Nov 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.